Table 1.
Associations of NLR, PLR, SII and clinicopathologic characteristics in 376 patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.
| Parameters | All | NLR | PLR | SII | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >2.9 | ≤2.9 | p-Value | >150 | ≤150 | p-Value | >485 | ≤485 | p-Value | ||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| Age | 0.006 | <0.001 | 0.972 | |||||||
| ≤70 | 208 (55.3) | 70 (46.7) | 138 (61.1) | 28 (35.9) | 180 (60.4) | 116 (55.2) | 92 (55.4) | |||
| >70 | 168 (44.7) | 80 (53.1) | 88 (38.9) | 50 (64.2) | 118 (39.6) | 94 (44.8) | 74 (44.6) | |||
| Gender | 0.214 | 0.263 | 0.601 | |||||||
| Male | 146 (38.8) | 64 (42.7) | 82 (36.3) | 26 (33.3) | 120 (40.3) | 84 (40.0) | 62 (37.3) | |||
| Female | 230 (61.2) | 86 (57.3) | 144 (63.7) | 52 (66.7) | 178 (59.7) | 126 (60.0) | 104 (62.7) | |||
| Hematuria | 0.296 | 0.196 | 0.681 | |||||||
| No | 83 (22.1) | 29 (19.3) | 54 (23.9) | 13 (16.7) | 70 (23.5) | 48 (22.9) | 35 (21.1) | |||
| Yes | 293 (77.9) | 121 (80.7) | 172 (76.1) | 65 (83.3) | 228 (76.5) | 162 (77.1) | 131 (78.9) | |||
| Symptomatic hydronephrosis | 0.014 | 0.572 | 0.021 | |||||||
| No | 330 (87.8) | 124 (82.7) | 206 (91.2) | 67 (85.9) | 263 (88.3) | 177 (84.3) | 153 (92.2) | |||
| Yes | 46 (12.2) | 26 (17.3) | 20 (8.8) | 11 (14.1) | 35 (11.7) | 33 (15.7) | 13 (7.8) | |||
| Bladder cancer history | 0.263 | 0.989 | 0.025 | |||||||
| No | 275 (73.1) | 105 (70.0) | 170 (75.2) | 57 (73.1) | 218 (73.2) | 144 (68.6) | 131 (78.9) | |||
| Yes | 101 (26.9) | 45 (30.0) | 56 (24.8) | 21 (26.9) | 80 (26.8) | 66 (31.4) | 35 (21.1) | |||
| BMI | 0.056 | 0.096 | 0.462 | |||||||
| >27 | 62 (16.5) | 18 (12.0) | 44 (19.5) | 8 (10.3) | 54 (18.1) | 32 (15.2) | 30 (18.1) | |||
| ≤27 | 314 (83.5) | 132 (88.0) | 182 (80.5) | 70 (89.7) | 244 (81.9) | 178 (84.8) | 136 (81.9) | |||
| ESRD | 0.044 | 0.479 | 0.151 | |||||||
| No | 300 (79.8) | 112 (74.7) | 188 (83.2) | 60 (76.9) | 240 (80.5) | 162 (77.1) | 138 (83.1) | |||
| Yes | 76 (20.2) | 38 (25.3) | 38 (16.8) | 18 (23.1) | 58 (19.5) | 48 (22.9) | 28 (16.9) | |||
| Anemia | 0.016 | <0.001 | 0.127 | |||||||
| No | 138 (36.7) | 44 (29.3) | 94 (41.6) | 14 (17.9) | 124 (41.6) | 70 (33.3) | 68 (41.0) | |||
| Yes | 238 (63.3) | 106 (70.7) | 132 (58.4) | 64 (82.1) | 174 (58.4) | 140 (66.7) | 98 (59.0) | |||
| CKD stage | 0.053 | 0.223 | 0.699 | |||||||
| Stage 1 | 36 (9.6) | 6 (4.0) | 30 (13.3) | 4 (5.1) | 32 (10.7) | 18 (8.6) | 18 (10.8) | |||
| Stage 2 | 78 (20.7) | 32 (21.3) | 46 (20.4) | 18 (23.1) | 60 (20.1) | 44 (21.0) | 34 (20.5) | |||
| Stage 3 | 154 (41.0) | 64 (42.7) | 90 (39.8) | 28 (35.9) | 126 (42.3) | 84 (40.0) | 70 (42.2) | |||
| Stage 4 | 24 (6.4) | 10 (6.7) | 14 (6.2) | 8 (10.3) | 16 (5.4) | 12 (5.7) | 12 (7.2) | |||
| Stage 5 | 84 (22.3) | 38 (25.3) | 46 (20.4) | 20 (25.6) | 64 (21.5) | 52 (24.8) | 32 (19.3) | |||
| Advanced CKD stage (Stage 4, 5) | 108 (28.7) | 48 (32.0) | 60 (26.5) | 0.253 | 28 (35.9) | 80 (26.8) | 0.116 | 64 (30.5) | 44 (26.5) | 0.398 |
| Type of operation | 0.304 | 0.712 | 0.093 | |||||||
| Open | 244 (64.9) | 48 (32.0) | 84 (37.2) | 52 (66.7) | 192 (66.4) | 144 (68.6) | 100 (60.2) | |||
| Laparoscopic | 132 (35.1) | 102 (68.0) | 142 (62.8) | 26 (33.3) | 106 (35.6) | 66 (31.4) | 66 (39.8) | |||
| Tumor location | 0.910 | 0.131 | 0.445 | |||||||
| Pyelocaliceal | 170 (45.2) | 68 (45.3) | 102 (45.1) | 42 (53.8) | 128 (43.0) | 98 (46.7) | 72 (43.4) | |||
| Ureteral | 132 (35.1) | 54 (36.0) | 78 (34.5) | 26 (33.3) | 106 (35.6) | 68 (32.4) | 64 (38.6) | |||
| Both | 74 (19.7) | 28 (18.7) | 46 (20.4) | 10 (12.8) | 64 (21.5) | 44 (21.0) | 30 (18.1) | |||
| Multifocality | 0.021 | 0.568 | 0.099 | |||||||
| Single | 298 (79.3) | 110 (73.3) | 188 (83.2) | 60 (76.9) | 238 (79.9) | 160 (76.2) | 138 (83.1) | |||
| Multiple | 78 (20.7) | 40 (26.7) | 38 (16.8) | 18 (23.1) | 60 (20.1) | 50 (23.8) | 28 (16.9) | |||
| Pathologic T stage | 0.001 | 0.018 | 0.017 | |||||||
| pTa/pTis/pT1 | 146 (38.8) | 46 (30.7) | 100 (44.2) | 26 (33.3) | 120 (40.3) | 70 (33.3) | 76 (45.8) | |||
| pT2 | 68 (23.4) | 38 (25.3) | 50 (22.1) | 20 (25.6) | 68 (22.8) | 52 (24.8) | 36 (21.7) | |||
| pT3 | 114 (30.3) | 46 (30.7) | 68 (30.1) | 20 (25.6) | 94 (31.5) | 66 (31.4) | 48 (28.9) | |||
| pT4 | 28 (7.4) | 20 (13.3) | 8 (3.5) | 12 (15.4) | 16 (5.4) | 22 (10.5) | 6 (3.6) | |||
| Advanced pT stage (pT3, pT4) | 0.042 | 0.505 | 0.063 | |||||||
| No | 234 (62.2) | 84 (56.0) | 150 (66.4) | 46 (59.0) | 188 (63.1) | 122 (58.1) | 112 (67.5) | |||
| Yes | 142 (37.8) | 66 (44.0) | 76 (33.6) | 32 (41.0) | 110 (36.9) | 88 (41.9) | 54 (32.5) | |||
| Pathologic N stage | 0.659 | 0.479 | 0.003 | |||||||
| pN0 | 68 (18.1) | 23 (15.3) | 36 (15.9) | 22 (22.4) | 42 (14.1) | 31 (14.8) | 35 (21.1) | |||
| pNx | 232 (61.7) | 95 (63.3) | 146 (64.6) | 58 (59.2) | 198 (66.4) | 125 (59.5) | 109 (65.7) | |||
| pN+ | 76 (20.2) | 32 (21.3) | 44 (19.5) | 18 (23.1) | 58 (19.5) | 54 (25.7) | 22 (13.3) | |||
| Grade | 0.257 | 0.941 | 0.527 | |||||||
| Low | 76 (20.2) | 26 (17.3) | 50 (22.1) | 16 (20.5) | 60 (20.1) | 40 (19.0) | 36 (21.7) | |||
| High | 300 (79.8) | 124 (82.7) | 176 (77.9) | 62 (79.5) | 238 (79.9) | 170 (81.0) | 130 (78.3) | |||
| Concomitant CIS | 0.323 | 0.235 | 0.028 | |||||||
| No | 331 (88.0) | 129 (86.0) | 202 (89.4) | 62 (79.5) | 169 (85.4) | 178 (84.8) | 153 (92.2) | |||
| Yes | 45 (12.0) | 21 (14.0) | 24 (10.6) | 16 (20.5) | 29 (14.6) | 32 (15.2) | 13 (7.8) | |||
| Adjuvant chemotherapy | 0.015 | 0.009 | <0.001 | |||||||
| No | 308 (81.9) | 114 (76.0) | 194 (85.8) | 56 (71.8) | 252 (84.6) | 158 (75.2) | 150 (90.4) | |||
| Yes | 68 (18.1) | 36 (24.0) | 32 (14.2) | 22 (28.2) | 46 (15.4) | 52 (24.8) | 16 (9.6) | |||
| NLR | <0.001 | <0.001 | ||||||||
| >2.9 | - | - | - | 76 (97.4) | 74 (24.8) | 140 (66.7) | 10 (6.0) | |||
| ≤2.9 | - | - | - | 2 (2.6) | 224 (75.2) | 70 (33.3) | 156 (94.0) | |||
| PLR | <0.001 | <0.001 | ||||||||
| >150 | 78 (20.7) | 76 (50.7) | 2 (0.9) | - | - | 78 (37.1) | 0 (0.0) | |||
| ≤150 | 298 (79.3) | 74 (49.3) | 224 (99.1) | - | - | 132 (62.9) | 166 (100.0) | |||
| SII | <0.001 | <0.001 | ||||||||
| >485 | 210 (55.9) | 140 (93.3) | 70 (31.0) | 78 (100.0) | 132 (44.3) | - | - | |||
| ≤485 | 166 (44.1) | 10 (6.7) | 156 (69.0) | 0 (0.0) | 166 (55.7) | - | - | |||
CKD = chronic kidney disease; ECOG = Eastern Cooperative Oncology Group; ESRD = end stage renal disease; NLR = neutrophile-lymphocyte ratio; PLR = Platelet-lymphocyte ratio; SII = systemic immune-inflammation index. Statistically significant values are marked with Bold.